On November 9, 2021 HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, reported it had licensed exclusive worldwide ex-China rights to the Wee1 inhibitor from Shanghai Pharma, the second largest pharma group in China with annual sales of over $30 billion (Press release, HUYA Bioscience, NOV 9, 2021, View Source [SID1234594927]). This is the first program that Shanghai Pharma has outlicensed to a global partner.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"HUYABIO International has pioneered an innovative approach for partnering with Chinese research institutions and pharmaceutical companies. It identifies and licenses the most promising pre-clinical and clinical stage compounds in China, leverages and extends the research efforts of its Chinese partners, and provides a bridge into the international development process and global biopharma market. We are glad to collaborate with them on our SPH6162 as this collaboration is an important milestone of our global strategy due to our Licensed Molecules and Licensed Products," said Min Zuo, CEO Shanghai Pharmaceuticals.
Wee1 regulates the G2 checkpoint and stimulates entry into mitosis in response to DNA damage. It is a nuclear kinase belonging to the Ser/Thr family of protein kinases and its cell size by inhibiting Cdk1. Wee1 over-expression has been observed in solid tumors including hepatocellular carcinoma, colon cancer, glioblastoma, non-small-cell lung cancer (NSCLS), neuroblastoma, and gastric cancers.
Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO, said, "We are delighted to partner with Shanghai Pharmaceuticals for a therapeutic mechanism that promises broad synergy across treatments for many tumor types. HUYABIO is the first global company with which Shanghai Pharma has signed a major outlicensing agreement and we look forward to co-development of this innovative program in China."